RayKnowChina Research Map
Shortlist0

Chinese PLA General Hospital

中国人民解放军总医院

BeijingUniversity or health system

Hospitals that carry this university's name, added together, plus papers and trials that name only the university.

Research activity, not treatment quality. Not medical advice. How this works

Nasopharyngeal carcinoma

鼻咽癌
0.3%Leads under 1 in 100 of China's research papers on NPC

Led 8 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.4%).

Run this PubMed search

Open trials led
0
Research papers it led
8
Trials it led
1
Share of China's trials
0.2%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 2220222023: 0020232024: 0020242025: 222025
ThemesRadiotherapy techniqueSide effects & quality of lifeImaging & AI

Hospitals counted here

  1. Chinese PLA General Hospital8

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Oesophageal squamous cell carcinoma

食管鳞状细胞癌
0.9%Leads under 1 in 100 of China's research papers on ESCC

Led 27 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.9%).

Run this PubMed search

Open trials led
0
Research papers it led
27
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.6%
Papers led per year
2021: 0020212022: 1120222023: 2220232024: 1120242025: 112025
ThemesMolecular markers & genomicsImmunotherapyEarly detection & endoscopy

Hospitals counted here

  1. Chinese PLA General Hospital27

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 st2023The Lancet. OncologyRCT
  2. Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2).2022Nature communicationsRCTFree full text
  3. First-Line Tislelizumab Plus Chemotherapy for Esophageal Squamous Cell Carcinoma with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-306.2025Advances in therapyFree full text
  4. Spatial proteomic profiling elucidates immune determinants of neoadjuvant chemo-immunotherapy in esophageal squamous cell carcinoma.2024Oncogene
  5. Long-term efficacy and predictors of pembrolizumab-based regimens in patients with advanced esophageal cancer in the real world.2023World journal of gastroenterologyFree full text
Trials on ClinicalTrials.gov6
  1. Study of Larotinib in Unresectable Advanced or Recurrent Esophageal CancerRecruitingNCT04415853Study sitePhase 3Start 2021-01
  2. Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal CancerActive, not recruitingNCT06247956Study sitePhase 2Start 2024-03
  3. A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid TumorsTerminatedNCT05427396Study sitePhase 1Start 2022-07
  4. KN046 in Subjects With Late Stage Esophageal Squamous Cell CarcinomaCompletedNCT03925870Study sitePhase 2Start 2019-06
  5. A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03783442Study sitePhase 3Start 2018-12
  6. BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction CarcinomaCompletedNCT03469557Study sitePhase 2Start 2017-07

PubMed searchClinicalTrials.gov

Hepatocellular carcinoma

肝细胞癌
1.2%Leads about 1 in 80 of China's research papers on HCC

Led 184 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (5.5%).

Run this PubMed search

Open trials led
6
Research papers it led
184
Trials it led
29
Share of China's trials
2.0%
Share of the world's papers
0.6%
Papers led per year
2021: 0020212022: 1120222023: 2220232024: 1120242025: 112025
ThemesRecurrence & prognosisImmunotherapy & targeted drugsLocal treatment (ablation, TACE, HAIC)

Hospitals counted here

  1. Chinese PLA General Hospital184

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial.2025Signal transduction and targeted therapyRCTFree full text
  2. Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B.2022Journal of hepatologyRCT
  3. The utility of P-I-R classification in predicting the on-treatment histological and clinical outcomes of patients with hepatitis B and advanced liver fibrosis.2024Hepatology (Baltimore, Md.)RCTFree full text
  4. High-risk population of progressive hepatic fibrosis in chronic hepatitis B patients on antiviral therapy.2023Journal of gastroenterologyRCT
  5. Peripheral immune factors aiding clinical parameter for better early recurrence prediction of hepatocellular carcinoma after thermal ablation.2023International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia GroupRCT
Trials on ClinicalTrials.gov6
  1. Fusing Ultrasound and Magnetic Resonance Imaging to Intelligently Plan Highly Conformal Ablation Thermal Field for Hepatocellular CarcinomaNot yet recruitingNCT06798194Lead sponsorStart 2025-01
  2. PIN in Combination With Anti-PD1 in Previously Treated Primary Hepatocellular CarcinomaRecruitingNCT07018518Lead sponsorPhase 1Start 2025-06
  3. CAR-T Cell Therapy Targeting GPC3 in Patients with Advanced GPC3-Positive Hepatocellular CarcinomaNot yet recruitingNCT06641453Lead sponsorPhase 1/Phase 2Start 2024-11
  4. Image Driven Hepatocellular Carcinoma Invasiveness Evaluation ResearchRecruitingNCT06559761Lead sponsorStart 2023-01
  5. To Compare the Efficacy of Microwave Ablation and Laparoscopic Hepatectomy for Hepatocellular CarcinomaRecruitingNCT04365751Lead sponsorN/AStart 2019-12
  6. Combination Therapy of Microwave Ablation and Cellular Immunotherapy for Hepatocellular CarcinomaRecruitingNCT02851784Lead sponsorPhase 2/Phase 3Start 2009-12

PubMed searchClinicalTrials.gov

Stomach cancer

胃癌
1.4%Leads about 1 in 70 of China's research papers on Stomach cancer

Led 140 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (3.9%).

Run this PubMed search

Open trials led
6
Research papers it led
140
Trials it led
28
Share of China's trials
1.9%
Share of the world's papers
0.7%
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 1120242025: 112025
ThemesEarly detection & endoscopyPeritoneal spread & advanced diseaseSurgery

Hospitals counted here

  1. Chinese PLA General Hospital140

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. 177Lu-Dotatate versus high-dose long-acting octreotide for the treatment of patients with advanced, grade 1-2, well-differentiated gastroenteropancreatic neuroendocrine tumours (XT-XTR008-3-01): an open-label, randomised2025Annals of oncology : official journal of the European Society for Medical OncologyRCT
  2. Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial.2023JAMARCTFree full text
  3. Perioperative versus adjuvant S-1 plus oxaliplatin chemotherapy for stage II/III resectable gastric cancer (RESONANCE): a randomized, open-label, phase 3 trial.2024Journal of hematology & oncologyRCTFree full text
  4. Diagnostic accuracy of linked colour imaging versus white light imaging for early gastric cancers: a prospective, multicentre, randomized controlled trial study.2022Annals of medicineRCTFree full text
  5. Effect of Postoperative ω-3 Fatty Acid Immunonutritional Therapy on NK Cell Gene Methylation in Elderly Patients with Gastric Cancer.2022Current medical scienceRCT
Trials on ClinicalTrials.gov6
  1. Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric CancerRecruitingNCT07392346Lead sponsorPhase 2Start 2025-12
  2. The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled TrialRecruitingNCT07212933Lead sponsorPhase 2Start 2025-07
  3. EGPSS for Weight Management in an in Vivo Human ModelEnrolling by invitationNCT07186959Lead sponsorN/AStart 2024-07
  4. Helicobacter Pylori Infection Status and Pathological Features for Predicting Gastric Cancer Biological Behavior and Prognosis: A Real-World Observational StudyRecruitingNCT07724496Lead sponsorStart 2024-01
  5. Prospective Observational Cohort StudyNot yet recruitingNCT06493448Lead sponsorStart 2024-07
  6. Oxaliplatin Combined With S-1(SOX) Neoadjuvant Chemotherapy for Different Cycles in Patients With Gastric CancerRecruitingNCT04483076Lead sponsorPhase 3Start 2021-01

PubMed searchClinicalTrials.gov

Hepatoblastoma

肝母细胞瘤
1.9%Leads about 1 in 51 of China's research papers on Hepatoblastoma ▼ from 3.5%

Led 3 of 154 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (13.6%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.7%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 1120242025: 002025

Hospitals counted here

  1. Chinese PLA General Hospital3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led3
  1. An update on diagnosis and treatment of hepatoblastoma.2024Bioscience trends
  2. FTO gene polymorphisms and hepatoblastoma susceptibility among Chinese children.2022Cell cycle (Georgetown, Tex.)
  3. Percutaneous thermal ablation versus open liver resection for recurrent hepatoblastoma: a retrospective study.2021International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group

PubMed searchClinicalTrials.gov

Retinoblastoma

视网膜母细胞瘤
0.7%Leads under 1 in 100 of China's research papers on Retinoblastoma New since 2021

Led 2 of 301 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 2220212022: 0020222023: 0020232024: 0020242025: 002025

Hospitals counted here

  1. Chinese PLA General Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Osteosarcoma

骨肉瘤
0.5%Leads under 1 in 100 of China's research papers on Osteosarcoma

Led 12 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
12
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 332025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Chinese PLA General Hospital12

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Gastrointestinal stromal tumour

胃肠道间质瘤
1.3%Leads about 1 in 75 of China's research papers on Gastrointestinal stromal tumour

Led 7 of 523 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.3%).

Run this PubMed search

Open trials led
0
Research papers it led
7
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 3320242025: 112025

Hospitals counted here

  1. Chinese PLA General Hospital7

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. The maximum transverse diameter: an effective indicator for predicting peroral en bloc retrieval rate of mesenchymal tumors after endoscopic resection.2025Surgical endoscopy
  2. Application of through-the-scope twin clip for defect closure after gastric gastrointestinal stromal tumor transoral super minimally invasive surgery resection.2024EndoscopyFree full text
  3. Endoscopic resection for the treatment of gastric gastrointestinal stromal tumors: a retrospective study from a large tertiary hospital in China.2024Surgical endoscopy
  4. Endoscopic resection of gastrointestinal stromal tumors.2024Journal of digestive diseases
  5. Endoscopic resection for the treatment of non-gastric gastrointestinal stromal tumors: A retrospective study from a large tertiary hospital in China.2023Clinics and research in hepatology and gastroenterology
Trials on ClinicalTrials.gov6
  1. A Novel Two-Tooth Clip for ESD and EFTR of GISTRecruitingNCT07581977Study siteN/AStart 2026-04
  2. A Study of HQP1351 in Patients With GIST or Other Solid TumorsRecruitingNCT03594422Study sitePhase 1Start 2018-07
  3. Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of ImatinibTerminatedNCT04409223Study sitePhase 3Start 2020-09
  4. A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)CompletedNCT04282980Study sitePhase 2Start 2020-04
  5. A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With ImatinibCompletedNCT04633122Study sitePhase 2Start 2020-11
  6. A Study of CS3007 in Subjects With Gastrointestinal Stromal TumorCompletedNCT04254939Study sitePhase 1/Phase 2Start 2019-08

PubMed searchClinicalTrials.gov

Neuroblastoma

神经母细胞瘤
0.09%Leads under 1 in 100 of China's research papers on Neuroblastoma

Led 1 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
1
Share of China's trials
2.4%
Share of the world's papers
0.02%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

Hospitals counted here

  1. Chinese PLA General Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Multiple myeloma

多发性骨髓瘤
0.3%Leads under 1 in 100 of China's research papers on Myeloma

Led 5 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.8%).

Run this PubMed search

Open trials led
2
Research papers it led
5
Trials it led
5
Share of China's trials
1.0%
Share of the world's papers
0.05%
Papers led per year
2021: 1120212022: 2220222023: 0020232024: 1120242025: 112025
ThemesDiagnosis, MRD & riskStem cell transplantKidney & bone complications

Hospitals counted here

  1. Chinese PLA General Hospital5

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. HLA-mismatched stem cell microtransplant prolonged overall survival and promoted immunological reconstitution for multiple myeloma.2025Frontiers in immunologyFree full text
  2. Percutaneous vertebroplasty combined with chemotherapy in the treatment of multiple myeloma patients with vertebral compression fractures.2022Chinese medical journalFree full text
  3. Clotrimazole inhibits growth of multiple myeloma cells in vitro via G0/G1 arrest and mitochondrial apoptosis.2024Scientific reportsFree full text
  4. Magnetic Resonance Imaging combined with Computed Tomography in the Diagnosis of Multiple Myeloma and the Killing Effect of Doxorubicin Nano-drug Delivery System on Myeloma Cells.2022Cellular and molecular biology (Noisy-le-Grand, France)
  5. Upregulation of ATIC in multiple myeloma tissues based on tissue microarray and gene microarrays.2021International journal of laboratory hematology
Trials on ClinicalTrials.gov6
  1. Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMARecruitingNCT07620275Lead sponsorPhase 1Start 2026-09
  2. Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal DysfunctionRecruitingNCT07489534Lead sponsorPhase 2Start 2025-09
  3. Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple MyelomaStatus unknownNCT04162119Lead sponsorPhase 2Start 2019-07
  4. A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple MyelomaStatus unknownNCT03767751Lead sponsorPhase 1/Phase 2Start 2018-12
  5. Treatment of Chemotherapy Refractory Multiple Myeloma by CART-138Status unknownNCT01886976Lead sponsorPhase 1/Phase 2Start 2013-06
  6. Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid TherapyCompletedNCT02609828Study sitePhase 3Start 2015-10

PubMed searchClinicalTrials.gov

B-cell acute lymphoblastic leukaemia (B-ALL)

B 细胞急性淋巴细胞白血病
0.0%Leads none of China's research papers on B-ALL

Led 0 of 225 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.9%).

Run this PubMed search

Open trials led
6
Research papers it led
0
Trials it led
12
Share of China's trials
4.7%
Share of the world's papers
0.0%

PubMed searchClinicalTrials.gov

Aplastic anaemia

再生障碍性贫血
0.2%Leads under 1 in 100 of China's research papers on Aplastic anaemia ▼ from 1.2%

Led 1 of 412 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
1
Research papers it led
1
Trials it led
3
Share of China's trials
3.1%
Share of the world's papers
0.06%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025
ThemesStem cell transplantChildren

Hospitals counted here

  1. Chinese PLA General Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Haemophagocytic lymphohistiocytosis (HLH)

噬血细胞性淋巴组织细胞增生症
0.5%Leads under 1 in 100 of China's research papers on HLH ▼ from 1.1%

Led 2 of 399 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.3%).

Run this PubMed search

Open trials led
1
Research papers it led
2
Trials it led
1
Share of China's trials
2.1%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025
ThemesEBV & infection triggersGenetics & inherited formsChildren

Hospitals counted here

  1. Chinese PLA General Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuromyelitis optica spectrum disorder (NMOSD)

视神经脊髓炎谱系疾病
2.5%Leads about 1 in 40 of China's research papers on NMOSD ▼ from 7.4%

Led 12 of 485 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.5%).

Run this PubMed search

Open trials led
2
Research papers it led
12
Trials it led
4
Share of China's trials
5.1%
Share of the world's papers
0.6%
Papers led per year
2021: 0020212022: 3320222023: 0020232024: 1120242025: 112025
ThemesAntibodies & diagnosisAcute attack treatmentOptic nerve & vision

Hospitals counted here

  1. Chinese PLA General Hospital12

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Nomogram for the prediction of relapse factors in patients with neuromyelitis optica spectrum disorder during rituximab treatment.2025Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  2. Rituximab maintenance treatment outcomes in patients with relapsing neuromyelitis optica spectrum disorder: a monocentric retrospective analysis.2024Acta neurologica Belgica
  3. Safety and efficacy of plasma exchange treatment in children with AQP4-IgG positive neuromyelitis optica spectrum disorder.2022Frontiers in immunologyFree full text
  4. Bilateral parafalcine cortical and leptomeningeal impairment in MOG antibody disease and AQP4 neuromyelitis optica.2022Journal of neuroimmunology
  5. Lower motor neuron involvement in patients with neuromyelitis optica spectrum disorders.2022Multiple sclerosis and related disorders
Trials on ClinicalTrials.gov6
  1. Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World StudyRecruitingNCT07410039Lead sponsorPhase 4Start 2026-02
  2. The Safety and Efficacy of KSVCBD Injection in Neuromyelitis Optica Spectrum Disorder.Not yet recruitingNCT07592754Lead sponsorEarly phase 1Start 2026-05
  3. A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)RecruitingNCT06413654Study sitePhase 2/Phase 3Start 2024-07
  4. Treatment of Relapsed and/or Refractory AQP4-IgG Seropositive NMOSD by Tandem CAR T Cells Targeting CD19 and CD20WithdrawnNCT03605238Lead sponsorPhase 1Start 2018-08
  5. Multimodel Magnetic Resonance Imaging (MRI)of Multiple Sclerosis and Neuromyelitis Optica Spectrum DisordersStatus unknownNCT02836327Lead sponsorStart 2014-09
  6. A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum DisordersActive, not recruitingNCT06044350Study sitePhase 2Start 2023-08

PubMed searchClinicalTrials.gov

IgG4-related disease

IgG4相关性疾病
2.0%Leads about 1 in 49 of China's research papers on IgG4-RD ▼ from 3.9%

Led 5 of 246 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (19.1%).

Run this PubMed search

Open trials led
2
Research papers it led
5
Trials it led
3
Share of China's trials
7.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 222025
ThemesDiagnosis & look-alikesPancreas & bile ductsHead, eye socket & salivary glands

Hospitals counted here

  1. Chinese PLA General Hospital5

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Myasthenia gravis

重症肌无力
0.8%Leads under 1 in 100 of China's research papers on Myasthenia gravis ▼ from 1.7%

Led 4 of 499 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.6%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 0020242025: 112025
ThemesAntibodies & diagnosis

Hospitals counted here

  1. Chinese PLA General Hospital4

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Moyamoya disease

烟雾病
12.9%Leads about 1 in 8 of China's research papers on Moyamoya ▲ from 7.0%

Led 46 of 356 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (19.9%).

Run this PubMed search

Open trials led
1
Research papers it led
46
Trials it led
2
Share of China's trials
6.1%
Share of the world's papers
3.7%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 442025
ThemesImaging & blood flowStroke & bleeding outcomesRevascularisation surgery

Hospitals counted here

  1. Chinese PLA General Hospital46

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Noninvasive Assessment of the Risk Features of Hemorrhage in Moyamoya Disease Using 7T MRI.2025NeurologyFree full text
  2. Champagne bottle neck sign predicts intracranial hemorrhage in Moyamoya disease: A long-term follow-up study.2026Clinical neurology and neurosurgery
  3. Optimizing Surgical Timing to Reduce Stroke Risk in Pediatric Moyamoya Disease.2025Stroke
  4. Clinical significance of postoperative collateral circulation formation in long-term prognosis and stroke events after EDAS in adults with moyamoya disease.2025Neurosurgical review
  5. Long-Term Outcomes in Patients With Hemorrhagic Moyamoya Disease Combined With Hypertension After Encephaloduroarteriosynangiosis.2025Journal of the American Heart AssociationFree full text
Trials on ClinicalTrials.gov6
  1. The Evolution and Prognosis of Moyamoya DiseaseRecruitingNCT05619068Lead sponsorStart 2022-09
  2. Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya SyndromeRecruitingNCT07894107Study siteStart 2026-08
  3. Predicative Value of Multimodal MRI in Moyamoya DiseaseStatus unknownNCT03785171Lead sponsorStart 2018-09
  4. Safety and Efficacy of RIC in Pediatric Moyamoya Disease Patients Treated With Revascularization TherapyStatus unknownNCT03546309Study siteN/AStart 2024-09
  5. Safety and Efficacy of Remote Ischemic Conditioning Combined EDAS on Ischemic Moyamoya DiseaseStatus unknownNCT04917003Study siteN/AStart 2021-06
  6. Effect of Surgical Revascularization on Hemorrhagic Moyamoya DiseaseStatus unknownNCT03627975Study siteN/AStart 2017-10

PubMed searchClinicalTrials.gov

Hepatic echinococcosis

肝包虫病
1.3%Leads about 1 in 76 of China's research papers on Hepatic echinococcosis

Led 2 of 152 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (32.2%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

Hospitals counted here

  1. Chinese PLA General Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Idiopathic pulmonary fibrosis

特发性肺纤维化
0.3%Leads under 1 in 100 of China's research papers on Idiopathic pulmonary fibrosis New since 2021

Led 3 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.08%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 2220242025: 002025

Hospitals counted here

  1. Chinese PLA General Hospital3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症
2.6%Leads about 1 in 39 of China's research papers on Amyotrophic lateral sclerosis ▼ from 4.9%

Led 20 of 779 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.3%).

Run this PubMed search

Open trials led
0
Research papers it led
20
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 3320242025: 002025

Hospitals counted here

  1. Chinese PLA General Hospital20

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Spinal muscular atrophy

脊髓性肌萎缩症
3.6%Leads about 1 in 27 of China's research papers on Spinal muscular atrophy New since 2021

Led 2 of 55 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (29.1%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

Hospitals counted here

  1. Chinese PLA General Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Fabry disease

法布雷病
4.1%Leads about 1 in 24 of China's research papers on Fabry disease New since 2021

Led 3 of 73 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.3%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

Hospitals counted here

  1. Chinese PLA General Hospital3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Pompe disease

庞贝病
3.3%Leads about 1 in 30 of China's research papers on Pompe disease ▼ from 6.2%

Led 1 of 30 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.7%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
1
Share of China's trials
11.1%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. Chinese PLA General Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Duchenne muscular dystrophy

杜氏肌营养不良
2.4%Leads about 1 in 43 of China's research papers on Duchenne muscular dystrophy

Led 5 of 213 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.8%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 332025

Hospitals counted here

  1. Chinese PLA General Hospital5

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgA nephropathy

IgA 肾病
2.3%Leads about 1 in 43 of China's research papers on IgA nephropathy ▼ from 5.6%

Led 17 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
1
Research papers it led
17
Trials it led
1
Share of China's trials
0.9%
Share of the world's papers
1.0%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 1120242025: 222025

Hospitals counted here

  1. Chinese PLA General Hospital17

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Osteogenesis imperfecta

成骨不全症
0.0%Leads none of China's research papers on Osteogenesis imperfecta

Led 0 of 99 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
0
Research papers it led
0
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.0%

PubMed searchClinicalTrials.gov

Primary biliary cholangitis

原发性胆汁性胆管炎
0.7%Leads under 1 in 100 of China's research papers on Primary biliary cholangitis

Led 2 of 300 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
3
Share of China's trials
6.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

Hospitals counted here

  1. Chinese PLA General Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Familial adenomatous polyposis

家族性腺瘤性息肉病
0.0%Leads none of China's research papers on Familial adenomatous polyposis

Led 0 of 59 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.2%).

Run this PubMed search

Open trials led
0
Research papers it led
0
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.0%

PubMed searchClinicalTrials.gov